PBYI Puma Biotechnology Inc

8.52
-0.36  -4%
Previous Close 8.88
Open 8.79
Price To Book 19.36
Market Cap 331,947,677
Shares 38,960,995
Volume 1,376,992
Short Ratio
Av. Daily Volume 1,669,205
Stock charts supplied by TradingView

NewsSee all news

  1. Puma Biotechnology Reports Third Quarter 2019 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for the third quarter 2019

  2. Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market

  3. Puma Biotechnology to Present at the Credit Suisse Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55

  4. Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial

  5. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released at ASCO June 3, 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 additional data due 4Q 2019.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data due 4Q 2019.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
PDUFA date late-April 2020.
Neratinib - NALA
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer
Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients.
Neratinib plus Kadcyla (T-DM1)
HER2-positive metastatic breast cancer

Latest News

  1. Puma Biotechnology Reports Third Quarter 2019 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for the third quarter 2019

  2. Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market

  3. Puma Biotechnology to Present at the Credit Suisse Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55

  4. Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial

  5. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

  6. FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

    Interim data from the Phase II CONTROL Trial showed that the addition of prophylactic treatment with loperamide plus budesonide reduced the rate of discontinuation due to neratinib-associated diarrhea to 11% versus a

  7. Puma Biotechnology to Present at Cantor Global Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 2:25

  8. Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for neratinib in

  9. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on September 4, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

  10. Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

    First regulatory approval of NERLYNX in Latin America. NERLYNX is the first approved therapy to reduce the risk of invasive disease recurrence in HER2-positive breast cancer patients following trastuzumab-based

  11. Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:35

  12. FDA Grants Orphan Drug Designation to Puma Biotechnology's NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases

    Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NERLYNX® (neratinib) for the treatment of breast cancer patients with brain